Journal
EMBO JOURNAL
Volume 32, Issue 22, Pages 2920-2937Publisher
WILEY
DOI: 10.1038/emboj.2013.207
Keywords
Abeta-oligomers; spastin; Tau missorting; MARK/par-1; Alzheimer disease
Categories
Funding
- DZNE
- MPG
- Wellcome Trust/MRC
- EU-FP7 (Memosad)
- Tau Consortium
Ask authors/readers for more resources
Mislocalization and aggregation of A beta and Tau combined with loss of synapses and microtubules (MTs) are hallmarks of Alzheimer disease. We exposed mature primary neurons to A beta oligomers and analysed changes in the Tau/MT system. MT breakdown occurs in dendrites invaded by Tau (Tau missorting) and is mediated by spastin, an MT-severing enzyme. Spastin is recruited by MT poly-glutamylation, induced by Tau missorting triggered translocalization of TTLL6 (Tubulin-Tyrosine-Ligase-Like-6) into dendrites. Consequences are spine loss and mitochondria and neurofilament mislocalization. Missorted Tau is not axonally derived, as shown by axonal retention of photo-convertible Dendra2-Tau, but newly synthesized. Recovery from A beta insult occurs after A beta oligomers lose their toxicity and requires the kinase MARK (Microtubule-Affinity-Regulating-Kinase). In neurons derived from Tau-knockout mice, MTs and synapses are resistant to A beta toxicity because TTLL6 mislocalization and MT polyglutamylation are prevented; hence no spastin recruitment and no MT breakdown occur, enabling faster recovery. Reintroduction of Tau re-establishes A beta-induced toxicity in TauKO neurons, which requires phosphorylation of Tau's KXGS motifs. Transgenic mice overexpressing Tau show TTLL6 translocalization into dendrites and decreased MT stability. The results provide a rationale for MT stabilization as a therapeutic approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available